COPD clinical trials in South Carolina
13 studies for COPD are looking for participants at sites in South Carolina.
Cities in South Carolina
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- AnMed Oglesby Center- Site Number : 8400074, Anderson
- MD First Research - Lancaster- Site Number : 8400102, Lancaster
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 22, 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- MedTrial- Site Number : 8400010, Columbia
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 15, 2026 · NCT07190222A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Lancaster
- Research Site, Spartanburg
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 9, 2026 · NCT07082738A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Anderson
- Research Site, Columbia
- Research Site, Gaffney
- and 2 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Rock Hill
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Bogan Sleep Consultants, LLC, Columbia
- Velocity Clinical Research, Gaffney, Gaffney
- Clinical Research of Rock Hill, Rock Hill
- and 1 more
RecruitingPhase 2/3
Ages 35 to 80 · All sexes · Updated Aug 31, 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Anderson
- Research Site, Charleston
- Research Site, Gaffney
- and 2 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Aug 26, 2026 · NCT06283966A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 101, Charleston
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Aug 11, 2026 · NCT07555483STRIVE Post-Market Registry Study
- AnMed Health, Anderson
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT04302272eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Greenville
- GSK Investigational Site, Rock Hill
RecruitingPhase 3
Ages 40 to 75 · All sexes · Updated Jul 28, 2026 · NCT07177339Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Spartanburg
- GSK Investigational Site, Union
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Apr 9, 2026 · NCT06961214Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
- GSK Investigational Site, Rock Hill
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 8, 2025 · NCT06959095Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Medical University of South Carolina (MUSC), Charleston
- McLeod Health, Florence
RecruitingObservational study
Ages 50 and older · All sexes · Updated Aug 5, 2025 · NCT06122077From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.